Literature DB >> 28567236

Emphysematous Cystitis: Mortality, Risk Factors, and Pathogens of a Rare Disease.

Andreas Schicho1, Christian Stroszczynski1, Philipp Wiggermann1.   

Abstract

Although high mortality rates have been reported for emphysematous pyelonephritis (EP), information on emphysematous cystitis (EC), which is less common, is sparse. Here, we report one new case of severe EC and 136 cases of EC that occurred between 2007 and 2016, and review information about the characteristics, diagnosis, treatment and mortality of these patients, and the pathogens found in these patients. The mean age of the 136 patients was 67.9±14.2 years. Concurrent emphysematous infections of other organs were found in 21 patients (15.4%), with emphysematous pyelonephritis being the most common of these infections. The primary pathogen identified was Escherichia coli (54.4%). Patients were mainly treated by conservative management that included antibiotics (n=105; 77.2%). Ten of the 136 patients with EC died, yielding a mortality rate of 7.4%. Despite the relatively low mortality rate of EC compared with that of EP, a high degree of suspicion must be maintained to facilitate successful and conservative management.

Entities:  

Keywords:  Pathogens; emphysematous cystitis; mortality; urinary tract infection

Year:  2017        PMID: 28567236      PMCID: PMC5432942          DOI: 10.4081/cp.2017.930

Source DB:  PubMed          Journal:  Clin Pract        ISSN: 2039-7275


Competing interest statement

Conflict of interest: the authors declare no potential conflict of interest.

Introduction

Emphysematous urinary tract infections (UTIs) are potentially life threatening. Although mortality rates of approximately 24% have been reported for emphysematous pyelonephritis (EP),[1] information on emphysematous cystitis (EC), which is less common, is sparse. The first case of pneumaturia, which was most likely a symptom of EC, was reported in Curiosities of Nature by Raciborsky in 1671.[2] Here, we report one new case of severe EC and 136 cases of EC that occurred between 2007 and 2016, and review information about the characteristics, diagnosis, treatment and mortality of these patients, and the pathogens found in these patients.

Brief Report

A 45-year old patient was admitted to our hospital with new diagnosed hepatic lesions of unknown dignity. Contrast-enhanced computed tomography (CT) of the abdomen revealed an advanced emphysematous cystitis involving the perirectal space (Figure 1A), and accompanying non-emphysematous, absceding prostatitis (Figure 1B). He had no fever, tachycardia or tachypnea, white blood cell count (WBC) was 13.9/nL, C-reactive protein (CRP) was 30.0 mg/L. He had a history of traumatic spinal cord injury L3 with intermittent selfcatheterization, and arterial hypertension. The identified pathogen was Klebsiella pneumoniae. Despite the urgent need for i.v. antibiotics, the patient dismissed himself from inpatient care on oral Co-Amoxiclav. He did not show up in our hospital for a short-term follow-up appointment.
Figure 1.

Contrast-enhanced computed tomography of the abdomen: A) emphyesematous cystitis involving the perirectal space; B) emphysematous cystitis with accompanying absceding prostatitis.

Discussion and Conclusions

Searching Medline for emphysematous cystitis and cystitis emphysematosa we found 140 articles; among the search results, 106 articles reported a total of 136 cases of EC. We recorded the following information for these cases, using Thomas et al.[3] as a reference: patient age, sex, and diabetes status; concurrent emphysematous infections involving other organs; urinary pathogens; white blood cell count (WBC); C-reactive protein (CRP) levels; treatment; imaging modality; and outcome. Incomplete data were allowed. The mean age of the 136 patients was 67.9±14.2 years (ranging from 11 to 96; the mean age for men was 65.7 years; the mean age for women was 69.3 years). A total of 83 patients were female (61.0%) and 46 were male (33.8%; the sex was not available for 7 patients). A total of 86 patients had diabetes (63.2%); there were 58 diabetic women (69.9%) and 26 diabetic men (56.5%). In 37 cases, plain radiography was used as the diagnostic tool (27.2%); CT (computed tomography) was used in 98 cases (72.0%), ultrasound was used in 9 cases (0.7%), and cystoscopy was used in 5 cases (0.4%). The mean WBC was 13.6±10.7 106/L (n=78) and the mean CRP level was 48.0±77.6 mg/dL (n=32) on admission. Concurrent emphysematous infections of other organs were found in 21 patients (15.4%), with emphysematous pyelonephritis being the most common of these infections. The primary pathogen identified from urinary cultures was Escherichia coli (54.4%; Table 1). Patients were mainly treated by conservative management that included antibiotics (n=105; 77.2%) and bladder drainage, with additional glycemic control in diabetic patients. Surgical treatment was reported to be necessary in 11 patients (8.1%), and included cystectomy and nephrectomy in concurrent EP. Ten of the 136 patients with EC died, yielding a mortality rate of 7.4%.
Table 1.

Patients’ characteristics and pathogens identified in these patients by urinary culture.

PatientsNo.%
Men4633.8
Women8361
Diabetic8663.2
Women with diabetes mellitus5833.8
Men with diabetes mellitus2614.7
Overall mortality rate107.4
Pathogen
Escherichia coli7454.4
Klebsiella pneumoniae1611.8
Enterobacter spp.42.9
Group D Streptococcus21.5
Enterococcus spp.21.5
Citrobacter spp.21.5
Klebsiella aerogenes10.7
Proteus mirabilis10.7
Acinetobacter baumannii10.7
Corynebacterium genitalium10.7
Candida spp.10.7
Aspergillus spp.10.7
EC is most often found in diabetic women who are in their 6th or 7th decade of life. Consistent with the female predominance of EC, we found a female-to-male ratio of 2.2:1 among the reported EC patients with diabetes; diabetic women showed an incidence rate of 91.5 per 1000 person-years for UTIs in general, whereas the rate was 28 in men.[4] Although most cases of EC are successfully treated by medical management that is built on an appropriate antibiotic regimen, more advanced cases of EC require surgical treatment. With a mortality rate of 7.4%, EC is markedly less life threatening than is EP. Although the pathogenesis of emphysematous UTIs, including EC, is not yet fully understood, gas-producing bacterial fermentation is required. Immunological host defense impairments, such as neurogenic bladder, immunosuppression, and diabetes, favor bacterial colonization of the urinary tract. Additionally, the increased availability of fermentation substrate in diabetic urine makes diabetic patients especially prone to emphysematous UTIs. Despite the relatively low mortality rate of EC compared with that of EP, a high degree of suspicion must be maintained to facilitate successful and conservative management.
  3 in total

1.  Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials.

Authors:  Niklas Hammar; Bahman Farahmand; Mikael Gran; Svante Joelson; Susan W Andersson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10-21       Impact factor: 2.890

2.  Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis.

Authors:  Matthew E Falagas; Vangelis G Alexiou; Konstantina P Giannopoulou; Ilias I Siempos
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

Review 3.  Emphysematous cystitis: a review of 135 cases.

Authors:  Anil A Thomas; Brian R Lane; Arun Z Thomas; Erick M Remer; Steven C Campbell; Daniel A Shoskes
Journal:  BJU Int       Date:  2007-05-17       Impact factor: 5.588

  3 in total
  11 in total

1.  Emphysematous cystitis: diagnosed only if suspected.

Authors:  Shanmugasundaram Rajaian; Pragatheeswarane Murugavaithianathan; Karrthik Krishnamurthy; Lakshman Murugasen
Journal:  BMJ Case Rep       Date:  2019-07-17

2.  Emphysematous cystitis: Retrospective evaluation of predisposing factors and ultrasound features in 36 dogs and 2 cats.

Authors:  Ilaria Lippi; Tommaso Mannucci; Daniele Della Santa; Gabriele Barella; Martina Oranges; Simonetta Citi
Journal:  Can Vet J       Date:  2019-05       Impact factor: 1.008

3.  Emphysematous pyelonephritis in an infant from Sokoto, north-western Nigeria.

Authors:  Fatima B Jiya; Paul K Ibitoye; Nma M Jiya; Maryam Amodu-Sanni; Yahaya Mohammed; Dada M Aquib; Lukman K Coker
Journal:  Afr J Lab Med       Date:  2021-04-26

Review 4.  Emphysematous pyelonephritis and cystitis: A case report and literature review.

Authors:  Shengxian Li; Jixue Wang; Jinghai Hu; Liang He; Chunxi Wang
Journal:  J Int Med Res       Date:  2018-06-19       Impact factor: 1.671

Review 5.  Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review.

Authors:  Qiang Wang; Meifeng Sun; Chengjun Ma; Hailin Lv; Peng Lu; Qi Wang; Guangyi Liu; Zhao Hu; Yanxia Gao
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

6.  Clinical Outcomes and Risk Factor Analysis of Patients Presenting with Emphysematous Cystitis: A 15-Year Retrospective Multicenter Study.

Authors:  Jeonghyouk Choi; Seung-Kwon Choi; Sang-Hyub Lee; Koo-Han Yoo
Journal:  Medicina (Kaunas)       Date:  2021-05-26       Impact factor: 2.430

7.  Concurrent Bilateral Emphysematous Pyelonephritis and Emphysematous Cystitis: A Case Report of Glomerulonephritis Severe Complication.

Authors:  Michał Godzisz; Przemysław Mitura; Damian Widz; Damian Sudoł; Iga Kuliniec; Krzysztof Bar
Journal:  Res Rep Urol       Date:  2021-06-21

8.  Bilateral emphysematous pyelonephritis cured by antibiotics alone in a black African woman.

Authors:  G Asafu Adjaye Frimpong; E Aboagye; P Amankwah; J Boateng; A S B Amoako-Adu
Journal:  Radiol Case Rep       Date:  2018-06-26

9.  Emphysematous cystitis: a cause of hematuria post angioplasty.

Authors:  Sarah Bouayyad; Sidney Parker; Jonathan Tam; Nisheeth Kansal; Vish Bhattacharya
Journal:  J Surg Case Rep       Date:  2020-02-19

10.  Emphysematous cystitis due to Streptococcus salivarius infection in a patient with a neurogenic bladder.

Authors:  Shuhei Okada; Yasushi Ichimura; Masahiro Iinuma
Journal:  IDCases       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.